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L I N K  TO  I N I T I A L  C O R R E S P O N D E N C E
We thank Professor Lentini for his com-
ments on our article (Minimum information 
about a bioactive entity (MIABE). Nature 
Rev. Drug Discov. 10, 661–669 (2011))1  
proposing guidelines for the minimum 
information about a bioactive entity 
(MIABE). In principle, the authors of the 
document agree that enantiomeric purity 
would be useful to include in the MIABE 
guidelines, and this could be added as an 
extension; it was always our intention that 
the MIABE document would be discussed 
and developed accordingly, rather than be 
a closed book. However, a few issues arose 
when enantiomeric purity was discussed 
during the preparation of the initial guide-
lines, and these have yet to be fully resolved, 
which led to its omission.
There are several general aspects of an 
impure compound (and we would regard 
an incompletely resolved compound as 
impure): first, we may not know precisely 
what is in the sample; second, there may be 
more than one potentially active compound 
in the sample; third, others repeating the 
experiment with different samples will  
probably have problems of reproducibility.
However, it is more valuable for someone to 
acknowledge that their sample is known to 
be impure than to pretend it is pure, so a flag 
indicating this is important. Enantiomeric 
mixtures are one of the harder types of com-
pound mixtures to separate, but they are not 
fundamentally different from other mixtures 
in terms of their representation. For a pure 
single enantiomer, the International Union 
of Pure and Applied Chemistry (IUPAC) 
International Chemical Identifier (InChI) 
string and/or other IUPAC names would be 
sufficient to describe the stereochemistry. 
For a compound that exists in two enantio-
meric forms, the additional information on 
the relative amounts in a given sample for 
which biological data are being reported 
needs to be specified if it can be, and has 
been, measured. There are two well-defined 
entities that InChI can describe: a single 
enantiomer and a racemate. Both are pure 
compounds. However, a sample with an 
enantiomeric excess is impure and should  
be treated in the same way as, for example,  
a mixture of unseparated cis-trans isomers,  
a mixture of compounds with partial or  
variable substitution or a mixture of anomers.
In conclusion, we feel more work needs 
to be done on extending the controlled 
vocabulary to fully describe the various 
types of compound mixtures noted above. 
Enantiomeric purity could then be added to 
the next revision of the MIABE guidelines.
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